U.S. market Closed. Opens in 11 hours 34 minutes

BIOR | Biora Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for BIOR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is very bad and Health is frighteningly weak.

Valuation (19%)

Company Industry
P/E Ratio (TTM) -0.27 -16.22
PEG Ratio (TTM) 0.01 -1.41
P/S Ratio (TTM) 13.69 48.82
P/B Ratio (TTM) -0.26 21.13
P/FCF Ratio (TTM) -0.49 9.38
Price to 5YR AVG Earnings Ratio -0.01 -0.21
Price to 5YR AVG FCF Ratio -0.21 -7.10

Profitability (50%)

Company Industry
ROA (TTM) -474.13% -3.10%
ROE (TTM) 84.54% 24.21%
Net Profit Margin (TTM) -4,999.48% -1,069.78%
ROIC 5YR AVG 288.95% 16.50%

Growth (35%)

4QTR AVG 3YR AVG 5YR AVG
EPS 40.17% 23.87% 26.97%
Revenue -44.79% -44.73% -61.69%
Net Income 23.42% -12.48% -23.79%
Cash Flow 0.48% -40.06% -6.79%

Health (7%)

Company Industry
Current Ratio (TTM) 0.20 5.75
Quick Ratio (TTM) 0.20 5.47
D/E Ratio (TTM) -0.52 -15.13
Interest Coverage (TTM) 24.29 3.59
Piotroski F-Score 2 5
Altman Z-Score N/A 13.47
LTL to 5YR AVG FCF -0.39 0.20
Shares Outstanding Growth 5YR AVG 73.91% 118.86%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙